Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

“…Although this presented an attractive rationale for the relative overexpression of Mcl-1 found in some CLL patients, the findings of this study were refuted by a much larger study of 173 CLL patients. 51 This study found no association between Mcl-1 promoter insertion sequences and V H gene status, Binet stage, or OS and concluded that they have no prognostic value in CLL.…”

Genetic alterations in chronic lymphocytic leukaemia

“…These alterations would appear to represent one of the most frequent somatic genomic alterations described in CLL patients. In contrast to these results, several authors reported that these MCL-1 insertions represent hereditary polymorphisms that likely do not predispose to CLL [41][42][43]. Very recently, the downregulation of the expression of DAPK1 (death-associated protein kinase 1) has been described, both genetically and epigenetically in familial and sporadic CLL [44].…”

Functional regulatory variants of MCL1 contribute to enhanced promoter activity and reduced risk of lung cancer in nonsmokers: Implications for context‐dependent phenotype of an antiapoptotic and antiproliferative gene in solid tumor

“…Several follow-up studies, however, argued against these findings and confirmed that the sequence insertions are not somatic oncogenic mutations but common hereditary polymorphisms, and they were not associated with clinical outcome of leukemia. [10][11][12][13][14][15][16] Even though correlation between the MCL1 promoter insertion and gene expression in leukemia was subsequently validated by Saxena et al, 17 its functional significance and clinical implications in solid cancer are still completely unknown.…”